Cervix News and Research

RSS

HPV vaccination programs may reduce genital diseases

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

6 Feb 2010

American Heart Month aims to spread awareness of women and heart disease

More than five times as many women are diagnosed with heart disease each year than with breast cancer. American Heart Month in February aims to spread awareness of women and heart disease, and one Alabama company has found the quickest way to a woman's heart might be through her gynecologist.

5 Feb 2010

DNA variants in mother and fetus can increase risk of preterm labor

Researchers at the National Institutes of Health have identified DNA variants in mothers and fetuses that appear to increase the risk for preterm labor and delivery.

4 Feb 2010

USPTO issues new patent for Advaxis' intellectual property portfolio

The U.S. Patent and Trademark Office (USPTO) issued today patent 7,635,479, "Compositions and Methods for Enhancing the Immunogenicity of Antigens,” by Dr. Yvonne Paterson, et al, which is assigned to the Trustees of the University of Pennsylvania and licensed to Advaxis, Incorporated (OTCBB: ADXS).

22 Jan 2010

HPV vaccine will reduce number of cervical cancer cases in women under 30

The number of women under 30 diagnosed with cervical cancer will fall nearly two thirds by 2025, thanks to the HPV vaccine.

20 Jan 2010

HPV testing could be used as standard method of cervical screening for women, say Italian scientists

Human papillomavirus (HPV) testing could be used as the standard method of cervical screening for women aged 35 years or older, as it seems to prevent more invasive cases of the disease than cytology screening alone, Italian scientists have said.

20 Jan 2010

NetApp, Stanford Genome Technology Center build gastric cancer registry powered by NetApp storage technology

Gastric cancer is the number two cancer killer worldwide and one of the top cancer killers in the U.S., but gastric cancer research gets the least federal funding of any type of cancer research. According to a CBS News analysis of data released by the American Cancer Society, for every cancer-related death in the U.S., only $1,168 federal research dollars are spent on gastric cancer, versus $18,870 for cancer of the cervix and $14,095 for breast cancer.

12 Jan 2010

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Scientists report cervarix vaccine offers protection against cervical cancer

The Cervarix vaccine provides protection against two types of human papillomavirus (HPV) for more than six years, US scientists have reported.

5 Dec 2009

New study links cigarette smoking with colorectal cancer

New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for other risk factors.

3 Dec 2009

MAbs for early detection of cancer

Two sets of recommendations issued earlier this month have revised longstanding guidelines concerning the age at which women should first be tested for breast and cervical cancer and how frequently.

1 Dec 2009

MRI can identify placenta accreta in pregnant women, reveals study

A study presented today at the annual meeting of the Radiological Society of North America (RSNA) revealed that MRI is a highly accurate means of identifying placenta accreta, a potentially life-threatening and increasingly common condition that is the leading cause of death for women just before and after giving birth.

1 Dec 2009

Study on deaths from cancer in Europe shows steady decline in mortality

New figures on deaths from cancer in Europe show a steady decline in mortality between the periods 1990-1994 and 2000-2004. Deaths from all cancers in the European Union (EU) between these two periods fell by nine percent in men and eight percent in women, with a large drop among the middle-aged population.

29 Nov 2009

Cook Medical unveils its uterine manipulator/injectors at 38th Global Congress of Minimally Invasive Gynecology

Laparoscopic surgeons received their first glimpse of Cook Medical’s uterine manipulator/injectors (UMI) last week at the 38th Global Congress of Minimally Invasive Gynecology, sponsored by the American Association of Gynecologic Laparoscopists (AAGL).

23 Nov 2009

Tips for preventing cancer

The risk of cancer can be dramatically reduced through everyday choices about diet, exercise and tobacco use, according to a Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource.

12 Nov 2009

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI).

6 Nov 2009

Columbia Laboratories reports net revenues of $7.9 million for third quarter 2009

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2009.

5 Nov 2009

Columbia Laboratories to raise funds through sale of its common stock and warrants

Columbia Laboratories, Inc. today announced that it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock.

24 Oct 2009

FMWC partners with SOGC and SCC to launch Pap test campaign

The Federation of Medical Women of Canada (FMWC) has joined forces with the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Society of Canadian Colposcopists (SCC) to launch this year's Pap test campaign during Cervical Cancer Awareness Week. Together, we hope to increase the scope, reach and impact of the campaign. With this collaborative effort, we aim to provide more Pap tests and deal with abnormal results in a more expeditious manner.

22 Oct 2009